These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 38647237)

  • 21. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction of a prognostic model for lung adenocarcinoma based on m6A/m5C/m1A genes.
    Ding H; Teng Y; Gao P; Zhang Q; Wang M; Yu Y; Fan Y; Zhu L
    Hum Mol Genet; 2024 Mar; 33(7):563-582. PubMed ID: 38142284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
    Ren J; Wang A; Liu J; Yuan Q
    Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA-seq and bulk RNA-seq data analysis of cancer-related fibroblasts (CAF) in LUAD to construct a CAF-based risk signature.
    Si Y; Zhao Z; Meng X; Zhao K
    Sci Rep; 2024 Oct; 14(1):23243. PubMed ID: 39369095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
    Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
    J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
    Xiao Y; Li J; Wu J
    BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma.
    Wang Z; Yao J; Dong T; Niu X
    J Immunol Res; 2022; 2022():2756611. PubMed ID: 36281357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of a new molecular subtyping and prognostic signature with m6A/m5C/m1A/m7G regulatory genes for hepatocellular carcinoma.
    Liu T; Wang Y; Li Z; Sun L; Yang K; Chen J; Han X; Qi L; Zhou X; Wang P
    Heliyon; 2023 Nov; 9(11):e21285. PubMed ID: 38027812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
    Wang Z; Chen X
    Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
    Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
    Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unlocking the Potential of Disulfidptosis-Related LncRNAs in Lung Adenocarcinoma: A Promising Prognostic LncRNA Model for Survival and Immunotherapy Prediction.
    Nie X; Ge H; Wu K; Liu R; He C
    Cancer Med; 2024 Oct; 13(20):e70337. PubMed ID: 39431755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
    Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
    Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G0 arrest gene patterns to predict the prognosis and drug sensitivity of patients with lung adenocarcinoma.
    Ma Y; Li Z; Li D; Zheng B; Xue Y
    PLoS One; 2024; 19(8):e0309076. PubMed ID: 39159158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
    Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
    J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel m6A/m5C/m1A/m7G-related classification and risk signature predicts prognosis and reveals immunotherapy inclination in gastric cancer.
    Chen R; Jiang L
    Transl Cancer Res; 2024 Jul; 13(7):3285-3298. PubMed ID: 39145046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a methyltransferase-related long noncoding RNA signature as a novel prognosis biomarker for lung adenocarcinoma.
    Sun YY; Li S; Liu C; Pan Y; Xiao Y
    Aging (Albany NY); 2024 May; 16(10):8747-8771. PubMed ID: 38771129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
    Zeng C; Yu H; Liu X; Liu Q; Jin J
    Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
    Sui P; Liu X; Zhong C; Sha Z
    Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
    Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
    J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.